Table 1.
Association between REV7 expression and clinicopathological factors in patients with ovarian cancer (n = 137)
| Variables | Patients (n) | REV7 expression score |
REV7 expression level |
P-value | ||||
|---|---|---|---|---|---|---|---|---|
| 0 (n = 11) | 1 (n = 43) | 2 (n = 43) | 3 (n = 40) | Low (n = 54) | High (n = 83) | |||
| Age, years | ||||||||
| <60 | 96 | 7 | 35 | 24 | 30 | 42 (43.8) | 54 (56.2) | 0.112 |
| ≥60 | 41 | 4 | 8 | 19 | 10 | 12 (29.3) | 29 (70.7) | |
| FIGO stage | ||||||||
| I | 50 | 5 | 10 | 19 | 16 | 15 (27.8) | 35 (70.0) | 0.087 |
| II–IV | 87 | 6 | 33 | 24 | 24 | 39 (44.8) | 48 (55.2) | |
| Histological type | ||||||||
| Clear cell | 49 | 0 | 13 | 13 | 22 | 13 (26.5) | 36 (73.5) | 0.021 |
| Non-clear cell | 88 | 11 | 30 | 29 | 18 | 41 (46.6) | 47 (53.4) | |
| Serous | 47 | 4 | 15 | 17 | 11 | 19 (40.4) | 28 (59.6) | |
| Mucinous | 19 | 2 | 4 | 6 | 7 | 6 (31.6) | 13 (68.4) | |
| Endometrioid | 22 | 5 | 11 | 6 | 0 | 16 (72.7) | 6 (27.3) | |
| Residual tumor | ||||||||
| Absent | 96 | 8 | 30 | 29 | 29 | 38 (39.6) | 58 (60.4) | 0.951 |
| Present | 41 | 3 | 13 | 14 | 11 | 16 (39.0) | 25 (61.0) | |
| CA125, U/mL | ||||||||
| <50 | 27 | 1 | 6 | 6 | 14 | 7 (25.9) | 20 (74.1) | 0.109 |
| ≥50 | 110 | 10 | 37 | 37 | 26 | 47 (42.7) | 63 (57.3) | |
| Chemotherapy (platinum-based) | ||||||||
| Absent | 18 | 2 | 5 | 4 | 7 | 7 (38.9) | 11 (61.1) | 0.961 |
| Present | 119 | 9 | 38 | 39 | 33 | 47 (39.5) | 72 (60.5) | |
FIGO, International Federation of Gynecology and Obstetrics.